Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Kenvue's has fired CEO Thibaut Mongon, who has also stepped down from the board, the consumer health company said on Monday, ...

Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, ...

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the ...

Echoing this, short-term traders are also sporting a call-bias. This is per the security's Schaeffer's put/call open interest ...

Kenvue stock approaches a Golden Cross, signaling bullish momentum with the stock up 10% over the past month. Legal win over Tylenol gelcaps boosts Kenvue's momentum, as strong brand power fuels ...

Why It Matters: Kenvue’s stock price has remained relatively unchanged this year, in contrast to the S&P 500 index’s 23% increase.The company’s biggest competitors include Haleon, the parent ...

Kenvue Non-GAAP EPS of $1.29 beats by $1.01, revenue of $3.7B misses by $90M Kenvue gains as ruling in Tylenol case likely collapses plaintiffs case - analyst Recommended For You ...

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the ...

Kenvue CEO Thibaut Mongon has stepped down as the company’s chief executive and departed its board of directors. The CEO of Tylenol maker Kenvue ( KVUE) has left the company as part of an internal ...